Volume 13, Number 2—February 2007
Research
Neutralizing Antibodies after Infection with Dengue 1 Virus
Gustavo Kourí*
, Mayling Alvarez*, Rosmari Rodriguez-Roche*, Lídice Bernardo*, Tibaire Montes†, Susana Vazquez*, Luis Morier*, Angel Alvarez*, Ernest A Gould‡, Maria G. Guzman* , and Scott B Halstead§
, Mayling Alvarez*, Rosmari Rodriguez-Roche*, Lídice Bernardo*, Tibaire Montes†, Susana Vazquez*, Luis Morier*, Angel Alvarez*, Ernest A Gould‡, Maria G. Guzman* , and Scott B Halstead§Table 1
Dengue virus strains used in this study
| Serotype | Strain | Passage no.* | Place and year of isolation |
|---|---|---|---|
| DENV-1† | Angola | 4PC6/36 1PVero 1PC6/36 | Angola, 1988 |
| DENV-2‡ | A15/81 | 4PMB 4PC6/36 | Cuba, 1981 |
| DENV-2†‡ | I348600 | 4P C6/36 | Colombia, 1986 |
| DENV-3 | 116/00 | 3P C6/36 | Cuba, 2000 |
| DENV-4† | Dominica | 7P C6/36 | Dominica, 1981 |
**P, passage; C6/36, Aedes albopictus cell line; Vero, green monkey kidney cell line; MB, mouse brain.
†DENV, dengue virus; received from Robert Shope, University of Texas Medical Branch, Galveston, Texas, USA.
‡DENV-2, A15/81 strain (Asian genotype), DENV 2, I348600 (American genotype).
